Genetic and pharmacologic enhancement of SUMO2 conjugation prevents and reverses cognitive impairment and synaptotoxicity in a preclinical model of Alzheimer's disease
Alzheimer's & Dementia · 2025-03 · 21 (3)
DOI: 10.1002/alz.70030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 06.03.2025. Verfasst von Luana Fioriti und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milano, MI, Italy. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction, Synapses, Small Ubiquitin-Related Modifier Proteins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NINDS NIH HHS, Fostering Joint International Research.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Amyloid beta oligomers (Aβos) are toxic to synapses and key to the progression of Alzheimer's disease (AD) and amyloid pathology, representing a target for therapeutic strategies. METHODS Amyloid and small ubiquitin modifier 2 ( SUMO2 ) transgenics were analyzed by electrophysiology and behavioral testing. A recombinant analogue of SUMO2, SBT02, was generated and assessed for brain penetration and the ability to mitigate amyloid pathology. RESULTS Elevated SUMO2 expression prevents cognitive and synaptic impairment in a mouse model of AD amyloid pathology. Systemic administration of SBT02 resulted in high brain bioavailability and prophylactically halted the progression of AD‐associated deficits. SBT02 also restored cognition and synaptic function in late‐stage amyloid load. Mechanistically, SUMO2 and SBT02 do not alter amyloid processing or clearance and mitigate synaptotoxicity in the presence of high amyloid loads. DISCUSSION SBT02 is a promising therapeutic strategy to counteract and reverse the toxic effects of Aβos in AD. Highlights Genetic overexpression of human SUMO2 prevents the long‐term potentiation (LTP) impairments and cognitive deficits in amyloid precursor protein (APP) transgenics without affecting amyloid pathology. A recombinant analogue of human SUMO2, termed SBT02, when administered systemically, displays high brain bioavailability and has no adverse effects at high doses. Prophylactic treatment of APP transgenics with SBT02 prior to the development of amyloid pathology results in the prevention of synaptic and behavioral dysfunction. SBT02 also reverses pre‐existing LTP and cognitive impairments when administered to APP transgenics with advanced and severe pathology. SBT02 has no impact on amyloid pathology, indicating a mechanism of action on synaptic resistance to Aβ toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milano, MI, Italy.
- Department of Pathology and Cell Biology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA.
- Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
- Department of Radiological Sciences, Faculty of Medical Science Technology, Morinomiya University of Medical Sciences, Suminoe Ward, Osaka, Japan.
- MINCL, Morinomiya University of Medical Sciences, Suminoe Ward, Osaka, Japan.
- Department of Child Development & Molecular Brain Science, United Graduate School of Child Development, Osaka University, Suita, Osaka, Japan.
Förderung
- NIH HHS
- NINDS NIH HHS
- Fostering Joint International Research
- Alzheimer's Association
- Japanese Society for the Promotion of Science
- CIHR
- Weston Brain Institute
- Grant-in-Aid for Scientific Research
Zitieren
APA
Fioriti, L., Wijesekara, N., Argyrousi, E. K., Matsuzaki, S., Takamura, H., Satoh, K., Han, K., Yamauchi, H., Staniszewski, A., Acquarone, E., Orsini, F., Martucci, A., Katayama, T., Arancio, O., & Fraser, P. E. (2025). Genetic and pharmacologic enhancement of SUMO2 conjugation prevents and reverses cognitive impairment and synaptotoxicity in a preclinical model of Alzheimer's disease. Alzheimer's & Dementia, 21(3). https://doi.org/10.1002/alz.70030
Vancouver
Fioriti L, Wijesekara N, Argyrousi EK, Matsuzaki S, Takamura H, Satoh K, et al. Genetic and pharmacologic enhancement of SUMO2 conjugation prevents and reverses cognitive impairment and synaptotoxicity in a preclinical model of Alzheimer's disease. Alzheimer's & Dementia. 2025;21(3). doi:10.1002/alz.70030
BibTeX
@article{Fioriti2025,
author = {Fioriti, Luana and Wijesekara, Nadeeja and Argyrousi, Elentina K and Matsuzaki, Shinsuke and Takamura, Hironori and Satoh, Kanayo and Han, Kyung and Yamauchi, Hiroto and Staniszewski, Agnieszka and Acquarone, Erica and Orsini, Franca and Martucci, Annacarla and Katayama, Taiichi and Arancio, Ottavio and Fraser, Paul E},
title = {Genetic and pharmacologic enhancement of SUMO2 conjugation prevents and reverses cognitive impairment and synaptotoxicity in a preclinical model of Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {3},
doi = {10.1002/alz.70030}
}
EUVIMED